| Line Item | 2022-03-31 | Y/Y |
|---|---|---|
| Revenue | $0 | -100.0% |
| Cost of Revenue | $0 | -100.0% |
| R&D Expense | $5.6M | +33.2% |
| SG&A Expense | $9.3M | +67.8% |
| Operating Income | -$15.6M | +5.1% |
| Pre-tax Income | -$10.5M | +46.8% |
| Income Tax | -$648K | — |
| Net Income | -$9.8M | +50.1% |
| Line Item | 2022-03-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $30.3M | -40.4% |
| Short-term Investments | $13.3M | +36.1% |
| Accounts Receivable | $548K | +3.4% |
| Current Assets | $45.5M | -27.0% |
| Total Assets | $128.6M | +105.9% |
| Current Liabilities | $3.3M | +106.5% |
| Total Liabilities | $20.4M | +199.4% |
| Line Item | 2022-03-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$17.2M | -20.4% |
| Investing Cash Flow | -$3.5M | +64.3% |
| Financing Cash Flow | $0 | -100.0% |
| Stockholders' Equity |
| $108.3M |
| +94.5% |